Star Tribune

Learn with Biosimilar Basics. Part 1 starts with an overview of biosimilar products, sharing what biosimilar drugs are and the difference vs generic drugs.

Shortages in the manufacturing chain have led to label hopping and an increase in off-label use

In the latest episode of the “Pharmacy Friends” podcast, hear about a new clinical report from Prime Therapeutics that dives into the latest evidence-based insights related to the rising prevalence...

publications Cell & Gene Pipeline Outlook: November 2025 Tracking the therapies shaping tomorrow’s care November 12, 2025 Editor-in-chief's message Welcome to Prime Therapeutics’ (Prime) inaugural...

The American Journal of Managed Care (AJMC): The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still...

CNN: At 37:03, listen to fitness expert Jillian Michaels cite Prime/Magellan Rx research on a podcast recording of a June 21 CNN broadcast

Maryam Tabatabai, PharmD, associate vice president of clinical information, shares more about how cell and gene therapies are transforming the treatment landscape, and how payers and providers can...

Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care

PUBLICATIONS FDA Decisions Expected: August 2025 Your monthly synopsis of new drugs expected to hit the market July 16, 2025 Drug pipeline for August 2025 At Prime Therapeutics (Prime), we have...

Managed Healthcare Executive: Use of GLP-1 drugs and weight-loss care management programs need to focus on adherence and persistency for better health outcomes, suggests Prime...

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Support your members with diabetes and obesity We help members navigate the challenges of diabetes and obesity with our holistic, customized approach to care. Breadcrumb Home Our solutions...

Academy of Managed Care Pharmacy (AMCP)'s Annual Meeting gathers thousands of health plan, pharmacy benefit management and biopharmaceutical experts to help define the future of managed care pharmacy.

Experience pharmacy solutions built for you Get holistic, people-centered solutions that help you save money while delivering a better member experience. Breadcrumb Home Who we are About us...

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care

From research posters and education sessions to the Pharmacy Friends podcast, Prime has you covered on the latest managed care pharmacy insights

Prime’s industry-leading research on GLP-1s was recognized at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting in Houston

Forbes

Read Drug Approvals Monthly Update: March 2024 Critical updates in an ever-changing environment Drug Approval Update Specialty New drugs 3/13/2024 Tevimbra™ (tislelizumab-jsgr) Tevimbra, a...

U.S. News & World Report

Specialty Pharmacy Continuum

Forbes

Publications Clinical Highlights: November 2024 Your monthly source for drug information highlights. November 27, 2024 Weight Management Corner: catch up on recent publications and study findings...

Gene therapy harnesses the body’s capacity to heal itself

Managed Healthcare Executive: Prior authorization using integrated medical claims data helps diabetes patients get medications faster, with two-thirds processed automatically by July 2025 in this...

Prime Therapeutics Report shares more about single-treatment gene therapies and proper management

Cover image for The evolution of GLP-1s Developing a holistic, individualized strategy to capitalize on opportunities and outcomes Prime Therapeutics /the-evolution-of-glp-1s About Prime...

New report explores traditional, specialty therapy trend impact to employers

publications Metabolic dysfunction–associated steatohepatitis (MASH) A new era in liver health: Treatment innovation, payer strategy, and pipeline momentum August 15, 2025 Prime Therapeutics’...

From next-gen CFTR modulators to gene therapy and real-world drug impact, cystic fibrosis care is constantly evolving. Maryam Tabatabai, PharmD, of Prime Therapeutics, explains how innovative...

Publications Clinical Highlights: February 2025 Your monthly source for drug information highlights. February 28, 2025 Trending topics The annual report Cancer statistics, 2025 from the American...

PUBLICATIONS FDA Decisions Expected: October 2025 Your monthly synopsis of new drugs expected to hit the market September 17, 2025 Drug pipeline for October 2025 At Prime Therapeutics (Prime), we...

cover image for Summer 2025 Issue: Clinical Insights – MASH A new era in liver health: Treatment innovation, payer strategy, and pipeline momentum Prime Therapeutics...

Learn with Biosimilar Basics. Part 2 covers biosimilar naming conventions and other nomenclature including common drug pipeline content acronyms.

publications High-Cost Therapy Profile: September 2025 Clemidsogene Ianparvovec Intracisternal | Regenxbio / Nippon Shinyaku Metabolic-gene therapy September 22, 2025 Proposed indications ...

Breadcrumb Home Newsroom Custom Content Publications Clinical Highlights: September 2024 PUBLICATIONS Clinical Highlights: September 2024 Your monthly source for drug information highlights....

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

A roundup of Prime's award-winning presentations and insights at AMCP Annual Meeting in Houston

Critical updates in an ever-changing environment